SPIC’s will ensure more predictability for pharmaceutical companies in Russia

Print 22 September 2017
GMP News

A meeting of the working group of the Coordination Council in the Area of Circulation of Medicines and Medical Devices held in the Russian Union of Industrialists and Entrepreneurs (RSPP) examined the state and development prospects of manufacturing the drugs for the treatment of oncological diseases in Russia.

In particular, the working group prepared draft proposals aimed at increasing Russian capacity in the development and manufacturing of anti-cancer drugs, as well as the effectiveness of public and private investments.

The participants of the meeting called to support the proposals of pharmaceutical companies for localizing the full-cycle manufacturing of high-tech oncological drugs in Russia and stimulating the transfer of reference drug technologies.

They also spoke in favor of strengthening state support for Russian and foreign manufacturers. Among other things, this includes the active conclusion of special investment contracts (SPICs) to stimulate the manufacturing of oncological and other innovative medicines.

Alexander Shokhin, the head of RSPP, called for developing these mechanisms in pharmaceutical industry and making them universal. “SPICs will ensure much more predictability for pharmaceutical companies,” he said.

According to Vladimir Shipkov, the Executive Director of AIPM, the fact that the pharmaceutical industry is outside the scope of international sanctions could become an additional driver for its development.

According to Elena Maksimkina, the Director of the Department of Drug Supply and Regulation of Medical Devices at the Ministry of Health of the Russian Federation, today, there are good opportunities for accelerating the launch of advanced imported drugs onto the Russian market. “But, in this area, there must be no automatic recognition,” she said. “Everything should proceed on a parity basis.”

Source

Return